Innovative Medicines for Tuberculosis relies on Resistell’s technology

Resistell, a leader in phenotypic nano-motion technology for measuring living cells, has entered a strategic partnership with the Innovative Medicines for Tuberculosis (iM4TB) foundation, a Swiss non-profit fighting tuberculosis (TB). The latter will deploy Resistell’s proprietary to further investigate its TB drug candidate, macozinone.